{"parse":{"title":"Xiamen Innovax Biotech","pageid":54815073,"revid":853079225,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Xiamen Innovax Biotech CO., LTD. (INNOVAX)</b> is a Chinese company that manufactures, markets, and develops vaccines. It is headquartered in Xiamen, China.<sup id=\"cite_ref-1\" class=\"reference\"><a href=\"#cite_note-1\">&#91;1&#93;</a></sup><sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Hepatitis_E_Vaccine_(HEV_239)\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Hepatitis E Vaccine (HEV 239)</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#Other_Vaccines\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">Other Vaccines</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#WHO_Position_on_HEV_239\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">WHO Position on HEV 239</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#References\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span id=\"Hepatitis_E_Vaccine_.28HEV_239.29\"></span><span class=\"mw-headline\" id=\"Hepatitis_E_Vaccine_(HEV_239)\">Hepatitis E Vaccine (HEV 239)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Xiamen_Innovax_Biotech&amp;action=edit&amp;section=1\" title=\"Edit section: Hepatitis E Vaccine (HEV 239)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In October 2012, Xiamen Innovax Biotech created the HEV 239 vaccine to treat Hepatitis E. The vaccine was approved by the Chinese Ministry of Science and Technology after it was tested during a controlled trial of 100,000+ people from the Jiangsu Province over a 12-month period. Of the 100,000 people treated, none were infected as compared to 15 that were infected from the controlled placebo group.<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> Xiamen Innovax Biotech used DNA recombinant technology to express the protein in E. coli which was then used as the base for the vaccine production.<sup id=\"cite_ref-10.1038/491021a_4-0\" class=\"reference\"><a href=\"#cite_note-10.1038/491021a-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Other_Vaccines\">Other Vaccines</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Xiamen_Innovax_Biotech&amp;action=edit&amp;section=2\" title=\"Edit section: Other Vaccines\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>Xiamen Innovax Biotech is responsible for creating a cervical cancer vaccine that is currently under a phase III clinical trial<sup id=\"cite_ref-6\" class=\"reference\"><a href=\"#cite_note-6\">&#91;6&#93;</a></sup>, a Genital Warts Vaccine that is under a phase II clinical trial<sup id=\"cite_ref-7\" class=\"reference\"><a href=\"#cite_note-7\">&#91;7&#93;</a></sup>, as well as a 9-valent HPV vaccine which is currently in the process of clinical approval.<sup id=\"cite_ref-WHO2013_8-0\" class=\"reference\"><a href=\"#cite_note-WHO2013-8\">&#91;8&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"WHO_Position_on_HEV_239\">WHO Position on HEV 239</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Xiamen_Innovax_Biotech&amp;action=edit&amp;section=3\" title=\"Edit section: WHO Position on HEV 239\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The <a href=\"/wiki/World_Health_Organization_(WHO)\" class=\"mw-redirect\" title=\"World Health Organization (WHO)\">World Health Organization (WHO)</a> stated that the Phase I, II, and III clinical trials were effective and safe in healthy subjects, however the WHO does not make a recommendation regarding the HEV 239 Vaccine because of a lack of evidence in people 16 years of age or younger, and 65 years of age and older. China is currently the only country to approve the HEV 239 vaccine since Hepatitis E is rare in developed countries. There are further clinical trials planned to make the drug available to susceptible populations.<sup id=\"cite_ref-WHO2015_9-0\" class=\"reference\"><a href=\"#cite_note-WHO2015-9\">&#91;9&#93;</a></sup> National authorities may however, decide to use the vaccine based on the local epidemiology.<sup id=\"cite_ref-WHO2015_9-1\" class=\"reference\"><a href=\"#cite_note-WHO2015-9\">&#91;9&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Xiamen_Innovax_Biotech&amp;action=edit&amp;section=4\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist\" style=\"list-style-type: decimal;\">\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-1\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://usa.chinadaily.com.cn/china/2012-10/27/content_15851542.htm\">\"First hepatitis E vaccine hits market in China\"</a>. <i>China Daily</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">August 8,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=China+Daily&amp;rft.atitle=First+hepatitis+E+vaccine+hits+market+in+China&amp;rft_id=http%3A%2F%2Fusa.chinadaily.com.cn%2Fchina%2F2012-10%2F27%2Fcontent_15851542.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.asianscientist.com/2012/01/pharma/china-approves-hepatitis-e-vaccine-hecolin-hev-239/\">\"China Approves World's First Hepatitis E Vaccine\"</a>. <i>Asian Scientist</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">August 8,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Asian+Scientist&amp;rft.atitle=China+Approves+World%E2%80%99s+First+Hepatitis+E+Vaccine&amp;rft_id=https%3A%2F%2Fwww.asianscientist.com%2F2012%2F01%2Fpharma%2Fchina-approves-hepatitis-e-vaccine-hecolin-hev-239%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"https://www.independent.co.uk/life-style/health-and-families/health-in-the-future-hepatitis-e-to-z-2061287.html\">\"Health in the Future: Hepatitis E to Z\"</a>. <i>Independent UK</i><span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">August 8,</span> 2017</span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Independent+UK&amp;rft.atitle=Health+in+the+Future%3A+Hepatitis+E+to+Z&amp;rft_id=https%3A%2F%2Fwww.independent.co.uk%2Flife-style%2Fhealth-and-families%2Fhealth-in-the-future-hepatitis-e-to-z-2061287.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-10.1038/491021a-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-10.1038/491021a_4-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Park, S. B. (November 2012). \"Hepatitis E vaccine debuts\". <i>Nature</i>. <b>491</b> (7422): 21\u201322. <a href=\"/wiki/Bibcode\" title=\"Bibcode\">Bibcode</a>:<a rel=\"nofollow\" class=\"external text\" href=\"http://adsabs.harvard.edu/abs/2012Natur.491...21P\">2012Natur.491...21P</a>. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1038/491021a\">10.1038/491021a</a>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/23128204\">23128204</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Nature&amp;rft.atitle=Hepatitis+E+vaccine+debuts&amp;rft.volume=491&amp;rft.issue=7422&amp;rft.pages=21-22&amp;rft.date=2012-11&amp;rft_id=info%3Apmid%2F23128204&amp;rft_id=info%3Adoi%2F10.1038%2F491021a&amp;rft_id=info%3Abibcode%2F2012Natur.491...21P&amp;rft.aulast=Park&amp;rft.aufirst=S.+B.&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Labrique, Alain B.; Sikder, Shegufta S.; Krain, Lisa J.; West, Keith P.; Christian, Parul; Rashid, Mahbubur; Nelson, Kenrad E. (2012-09-01). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3437697\">\"Hepatitis E, a Vaccine-Preventable Cause of Maternal Deaths\"</a>. <i>Emerging Infectious Diseases</i>. <b>18</b> (9): 1401\u20131404. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.3201/eid1809.120241\">10.3201/eid1809.120241</a>. <a href=\"/wiki/International_Standard_Serial_Number\" title=\"International Standard Serial Number\">ISSN</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.worldcat.org/issn/1080-6040\">1080-6040</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC3437697\">3437697</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/22931753\">22931753</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Emerging+Infectious+Diseases&amp;rft.atitle=Hepatitis+E%2C+a+Vaccine-Preventable+Cause+of+Maternal+Deaths&amp;rft.volume=18&amp;rft.issue=9&amp;rft.pages=1401-1404&amp;rft.date=2012-09-01&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3437697&amp;rft.issn=1080-6040&amp;rft_id=info%3Apmid%2F22931753&amp;rft_id=info%3Adoi%2F10.3201%2Feid1809.120241&amp;rft.aulast=Labrique&amp;rft.aufirst=Alain+B.&amp;rft.au=Sikder%2C+Shegufta+S.&amp;rft.au=Krain%2C+Lisa+J.&amp;rft.au=West%2C+Keith+P.&amp;rft.au=Christian%2C+Parul&amp;rft.au=Rashid%2C+Mahbubur&amp;rft.au=Nelson%2C+Kenrad+E.&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3437697&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-6\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\">Hu, Yuemei (October 2013). <a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4185883\">\"Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine\"</a>. <i>Human Vaccines &amp; Immunotherapeutics</i>. <b>52</b> (3): 218\u201323. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.4161/hv.26846\">10.4161/hv.26846</a>. <a href=\"/wiki/PubMed_Central\" title=\"PubMed Central\">PMC</a>&#160;<span class=\"plainlinks\"><a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pmc/articles/PMC4185883\">4185883</a>&#8239;<img alt=\"Freely accessible\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png\" title=\"Freely accessible\" width=\"9\" height=\"14\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/14px-Lock-green.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/18px-Lock-green.svg.png 2x\" data-file-width=\"512\" data-file-height=\"813\" /></span>. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/4185883\">4185883</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Human+Vaccines+%26+Immunotherapeutics&amp;rft.atitle=Safety+of+an+Escherichia+coli-expressed+bivalent+human+papillomavirus+%28types+16+and+18%29+L1+virus-like+particle+vaccine&amp;rft.volume=52&amp;rft.issue=3&amp;rft.pages=218-23&amp;rft.date=2013-10&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4185883&amp;rft_id=info%3Apmid%2F4185883&amp;rft_id=info%3Adoi%2F10.4161%2Fhv.26846&amp;rft.aulast=Hu&amp;rft.aufirst=Yuemei&amp;rft_id=%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC4185883&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-7\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-7\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://adisinsight.springer.com/drugs/800042287\">\"Human papillomavirus 6/11 vaccine recombinant bivalent\"</a>. <i>Adis Insight</i>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Adis+Insight&amp;rft.atitle=Human+papillomavirus+6%2F11+vaccine+recombinant+bivalent&amp;rft_id=http%3A%2F%2Fadisinsight.springer.com%2Fdrugs%2F800042287&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-WHO2013-8\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-WHO2013_8-0\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"http://who.int/immunization/research/meetings_workshops/HPV_endpoint_nov2013_report.pdf\">\"Meeting on Appropriate Clinical Endpoints for Second Generation HPV Vaccine Trials\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>WHO Immunization Research</i>: 1\u20132. 19 November 2013.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=WHO+Immunization+Research&amp;rft.atitle=Meeting+on+Appropriate+Clinical+Endpoints+for+Second+Generation+HPV+Vaccine+Trials&amp;rft.pages=1-2&amp;rft.date=2013-11-19&amp;rft_id=http%3A%2F%2Fwho.int%2Fimmunization%2Fresearch%2Fmeetings_workshops%2FHPV_endpoint_nov2013_report.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-WHO2015-9\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-WHO2015_9-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-WHO2015_9-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/wer/2015/wer9018.pdf?ua=1\">\"Hepatitis E vaccine: WHO position paper, May 2015\"</a> <span style=\"font-size:85%;\">(PDF)</span>. <i>Releve epidemiologique hebdomadaire</i>. <b>90</b> (18): 185\u2013200. 1 May 2015. <a href=\"/wiki/PubMed_Identifier\" class=\"mw-redirect\" title=\"PubMed Identifier\">PMID</a>&#160;<a rel=\"nofollow\" class=\"external text\" href=\"//www.ncbi.nlm.nih.gov/pubmed/25935931\">25935931</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Releve+epidemiologique+hebdomadaire&amp;rft.atitle=Hepatitis+E+vaccine%3A+WHO+position+paper%2C+May+2015.&amp;rft.volume=90&amp;rft.issue=18&amp;rft.pages=185-200&amp;rft.date=2015-05-01&amp;rft_id=info%3Apmid%2F25935931&amp;rft_id=http%3A%2F%2Fwww.who.int%2Fwer%2F2015%2Fwer9018.pdf%3Fua%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AXiamen+Innovax+Biotech\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div></div>\n\n<!-- \nNewPP limit report\nParsed by mw2253\nCached time: 20180917003834\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.112 seconds\nReal time usage: 0.140 seconds\nPreprocessor visited node count: 410/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 16828/2097152 bytes\nTemplate argument size: 86/2097152 bytes\nHighest expansion depth: 7/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 12515/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.055/10.000 seconds\nLua memory usage: 2.38 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  114.383      1 Template:Reflist\n100.00%  114.383      1 -total\n 56.87%   65.055      4 Template:Cite_web\n 21.49%   24.577      5 Template:Cite_journal\n  2.21%    2.532      1 Template:Main_other\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:54815073-0!canonical and timestamp 20180917003834 and revision id 853079225\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"","*":"Companies_based_in_China"},{"sortkey":"","*":"Vaccination-related_organizations"}],"links":[{"ns":0,"exists":"","*":"Bibcode"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"International Standard Serial Number"},{"ns":0,"exists":"","*":"PubMed Central"},{"ns":0,"exists":"","*":"PubMed Identifier"},{"ns":0,"exists":"","*":"World Health Organization (WHO)"}],"templates":[{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"}],"images":["Lock-green.svg"],"externallinks":["http://usa.chinadaily.com.cn/china/2012-10/27/content_15851542.htm","https://www.asianscientist.com/2012/01/pharma/china-approves-hepatitis-e-vaccine-hecolin-hev-239/","https://www.independent.co.uk/life-style/health-and-families/health-in-the-future-hepatitis-e-to-z-2061287.html","http://adsabs.harvard.edu/abs/2012Natur.491...21P","//doi.org/10.1038/491021a","//www.ncbi.nlm.nih.gov/pubmed/23128204","//www.ncbi.nlm.nih.gov/pmc/articles/PMC3437697","//doi.org/10.3201/eid1809.120241","//www.worldcat.org/issn/1080-6040","//www.ncbi.nlm.nih.gov/pubmed/22931753","//www.ncbi.nlm.nih.gov/pmc/articles/PMC4185883","//doi.org/10.4161/hv.26846","//www.ncbi.nlm.nih.gov/pubmed/4185883","http://adisinsight.springer.com/drugs/800042287","http://who.int/immunization/research/meetings_workshops/HPV_endpoint_nov2013_report.pdf","http://www.who.int/wer/2015/wer9018.pdf?ua=1","//www.ncbi.nlm.nih.gov/pubmed/25935931"],"sections":[{"toclevel":1,"level":"2","line":"Hepatitis E Vaccine (HEV 239)","number":"1","index":"1","fromtitle":"Xiamen_Innovax_Biotech","byteoffset":615,"anchor":"Hepatitis_E_Vaccine_(HEV_239)"},{"toclevel":1,"level":"2","line":"Other Vaccines","number":"2","index":"2","fromtitle":"Xiamen_Innovax_Biotech","byteoffset":2254,"anchor":"Other_Vaccines"},{"toclevel":1,"level":"2","line":"WHO Position on HEV 239","number":"3","index":"3","fromtitle":"Xiamen_Innovax_Biotech","byteoffset":3363,"anchor":"WHO_Position_on_HEV_239"},{"toclevel":1,"level":"2","line":"References","number":"4","index":"4","fromtitle":"Xiamen_Innovax_Biotech","byteoffset":4285,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Xiamen Innovax Biotech","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q41715074"}]}}